
Johan Westin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7675831/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Assessment of the FilmArray ME panel in 4199 consecutively tested cerebrospinal fluid samples. Clinical Microbiology and Infection, 2022, 28, 79-84.	6.0	19
2	Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. Scandinavian Journal of Gastroenterology, 2021, 56, 849-854.	1.5	1
3	Risk factors for norovirus infection in healthcare workers during nosocomial outbreaks: a cross-sectional study. Antimicrobial Resistance and Infection Control, 2021, 10, 107.	4.1	0
4	Pollen exposure weakens innate defense against respiratory viruses. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 576-587.	5.7	84
5	Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study. BMJ Open, 2020, 10, e035996.	1.9	1
6	Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infectious Diseases, 2018, 50, 569-583.	2.8	20
7	Viral Respiratory Tract Infection During the First Postoperative Year Is a Risk Factor for Chronic Rejection After Lung Transplantation. Transplantation Direct, 2018, 4, e370.	1.6	29
8	Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection. Journal of Hepatology, 2017, 67, 649-651.	3.7	5
9	Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. Infectious Diseases, 2017, 49, 561-575.	2.8	14
10	A four year seasonal survey of the relationship between outdoor climate and epidemiology of viral respiratory tract infections in a temperate climate. Journal of Clinical Virology, 2016, 84, 59-63.	3.1	67
11	Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scandinavian Journal of Gastroenterology, 2016, 51, 337-343.	1.5	13
12	Flocked nasal swab versus nasopharyngeal aspirate in adult emergency room patients: similar multiplex PCR respiratory pathogen results and patient discomfort. Infectious Diseases, 2016, 48, 246-250.	2.8	10
13	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. PLoS ONE, 2016, 11, e0155142.	2.5	10
14	A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol Accurately Predicts HCV-Related Liver Cirrhosis. PLoS ONE, 2014, 9, e93601.	2.5	6
15	Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology, 2014, 59, 2131-2139.	7.3	38
16	Norovirus GII.4 Detection in Environmental Samples from Patient Rooms during Nosocomial Outbreaks. Journal of Clinical Microbiology, 2014, 52, 2352-2358.	3.9	41
17	Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Transient Elastography in Chronic Hepatitis C Infection. PLoS ONE, 2013, 8, e80172.	2.5	22
18	Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3. PLoS ONE, 2012, 7, e29370.	2.5	32

JOHAN WESTIN

#	Article	IF	CITATIONS
19	PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Medical Genetics, 2012, 13, 82.	2.1	21
20	Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology, 2008, 47, 1837-1845.	7.3	196
21	Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology, 2008, 48, 695-695.	7.3	13
22	A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scandinavian Journal of Gastroenterology, 2008, 43, 73-80.	1.5	29
23	Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scandinavian Journal of Gastroenterology, 2005, 40, 867-872.	1.5	127
24	Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. Journal of Hepatology, 2002, 37, 837-842.	3.7	245